GRACE conference in Boston

Posted on September 28, 2014 by admin

There were several presentations as part of the Grace conference in Boston on Saturday, September 6. So far this is the only one I have found online.

PowerPoint presentation by Dr. Alice Shaw on 8 or 9 new ALK inhibitors and about various combination trials that have or will soon start. Also has a chart on various mutations and how some ALK inhibitors do against them.

http://www.oncology.tv/Portals/16/CancerGraceSlides/Shaw.pptx
Look below for a posted comment on other presentations from the conference.

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery. Bookmark the permalink.

One Response to GRACE conference in Boston

Leave a Reply